Meeting patients where treatment already happens

Kinimmune is developing KIN-112, an investigational immunotherapy designed to be administered when physicians already have access to a patient’s tumor through surgery or another planned procedure. By integrating treatment into established care workflows, our goal is to generate meaningful antitumor immune activity, with the long-term aim of improving outcomes for patients with solid tumors.